

December 21, 2009

Press release

[Mitsubishi Tanabe Pharma Corporation](#)

Name Change of Pharmaceutical Manufacturing & Sales Subsidiary in Korea (Welfide Korea Co., Ltd.)

Mitsubishi Tanabe Pharma Corporation (Head office: Osaka, Japan, President & CEO: Michihiro Tsuchiya) announced today that the company name of Welfide Korea Co. Ltd. (Head office: Hwaseong, Gyeonggi, Korea, President & CEO: Kozo Mizumoto), a consolidated subsidiary of Mitsubishi Tanabe Pharma Corporation, will be changed to Mitsubishi Tanabe Pharma Korea Co., Ltd., effective as of January 1, 2010.

Welfide Korea Co., Ltd. has continued its growth by engaging mainly in ethical drug businesses, including the manufacture and sale of prostaglandin E1 preparation, *Eglandin* (Japan product name: *Liple*) and the manufacture and export of synthetic adrenocorticosteroid preparation, *Lipotalon* (Japan product name: *Limethason*). Recent commencement of sales of *Herben* (Japan product name: *HERBESSER*) for the treatment of angina pectoris and hypertension, *Tanatril* for the treatment of hypertension, and *Depas*, the anxiolytic agent has further strengthened the operational foundation of the company.

On the occasion of this company name change, Mitsubishi Tanabe Pharma Korea will, as a strategic manufacturing and sales company in Korea, of the Mitsubishi Tanabe Pharma Corporation Group striving to be a global research-driven pharmaceutical company, endeavor to promote its presence in Korea.

Mitsubishi Tanabe Pharma Korea

Head Office: 903-4, Sangsin-ri, Hyangnam-eup, Hwaseong, Gyeonggi, Korea

President & CEO: Kozo Mizumoto

Capital stock: 2,100 million won

Shareholder: Mitsubishi Tanabe Pharma Corporation 100%

Net sales: Approx. 3.3 billion yen (Year ended December 2008)

Employees: 130 employees (as of September 30, 2009)

Major products: Eglandin, Herben, Tanatril, Depas

For Details, Contact the Following Section

Corporate Communications Dept., Mitsubishi Tanabe Pharma Corporation

Tel +81-6+6205-5211